Analyst Oren Livnat of H.C. Wainwright reiterated a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $73.00.
Oren Livnat has given his Buy rating due to a combination of factors that highlight the potential undervaluation and growth prospects of Tarsus Pharmaceuticals. Despite a recent dip in stock price, Livnat believes that concerns over cautious guidance and increased spending are misplaced. The company has consistently exceeded expectations with its XDEMVY product, leading to increased revenue projections for the coming years.
Livnat emphasizes the strong growth profile, high gross margins, and intellectual property extending to 2038, which make Tarsus an attractive investment. Furthermore, the potential for additional revenue from international markets and the development of new products in the lotilaner pipeline adds to the company’s upside. Livnat also notes that the current stock price makes Tarsus a potential acquisition target in the ophthalmology sector, reinforcing his Buy recommendation.
Livnat covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Avadel Pharmaceuticals, and Pacira Pharmaceuticals. According to TipRanks, Livnat has an average return of 0.0% and a 41.53% success rate on recommended stocks.